MARINUS PHARMACEUTICALS, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss income to net cash used in operating activities:
Gain from sale of PRV, net of transaction costs
Depreciation and amortization
Amortization of debt issuance costs
Accretion of revenue interest financing debt
Amortization of discount on short-term investments
Stock-based compensation expense
Loss on disposal of fixed assets
Noncash contract asset
Amortization of net contract asset/liability
Noncash lease expense
Noncash lease liability
Loss on fixed assets held for sale
Write off of fixed assets
Issuance of common stock for cost of license agreement
Unrealized loss on foreign currency transactions
Amortization of discount on investments
Changes in operating assets and liabilities:
Refund liability
Net contract asset/liability
Prepaid expenses and other current assets, non-current assets, and accounts receivable
Prepaid expenses and other current assets, non-current assets, inventory and accounts receivable
Accounts payable and accrued expenses

Net cash used in operating activities
Cash flows from investing activities
Proceeds from sale of PRV, net of transaction costs
Proceeds from sale of property and equipment
Maturities of short-term investments
Deposit on property and equipment
Purchases of short-term investments
Purchases of property and equipment
Net cash (used in) provided by investing activities
Cash flows from financing activities
Proceeds from exercise of stock options
Proceeds from notes payable, net of fees
Proceeds from revenue interest financing agreement, net of issuance costs
Payments of revenue interesting financing debt
Financing costs, paid
Proceeds from equity offerings, net of offering costs
Other cash flows from financing activities
Net cash provided by financing activities
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents-beginning of period
Cash and cash equivalents-end of period
Supplemental disclosure of cash flow information
Debt issuance costs included in accrued expenses
Increase in right-of-use asset and liability
Property and equipment in accrued expenses
Financing in accounts payable and accrued expenses
Operating lease liability
Operating right-of-use asset
Cash paid for interest during the year
Cash paid for income taxes during the year
Property and equipment in deposits placed in service

Comments